天疱疮治疗的研究进展  

Advances in the treatment of pemphigus

作　　者：周璐[1] 冯素英[1] 

机构地区：[1]中国医学科学院北京协和医学院皮肤病研究所,南京210042

出　　处：《国际皮肤性病学杂志》2011年第2期71-75,共5页International Journal of Dermatology and Venereology

基　　金：基金项目：国家自然科学基金（81071295）

摘　　要：天疱疮是一组威胁患者生命的自身免疫性大疱性疾病.传统的系统糖皮质激素和免疫抑制剂治疗虽可降低患者的死亡率,但常因其不良反应而限制了临床应用.随着对天疱疮发病机制研究的不断深入,一些新的治疗方法正逐步应用于临床或正处于试验研究阶段,如清除血清中的致病性抗体、生物制剂（CD20拮抗剂、肿瘤坏死因子-α拮抗剂）、p38促丝裂原活化蛋白激酶抑制剂、胆碱能受体激动剂、CD40/CD154阻断剂、桥粒芯蛋白3合成肽等.目前,由于上述药物价格昂贵、缺乏可靠的临床疗效数据或尚处于试验阶段等多种原因,尚未在临床治疗中广泛应用.emphigus is a group of life-threatening autoimmune blistering disorders. Although conventional therapies with systemic corticosteroids and immunosuppressive agents can reduce the mortality from pemphigus, complications have restricted their clinical application. With new insights into the pathogenesis of pemphigus, some novel treatment modalities, such as clearance of pathogenic antibodies in sera, biologic agents （CD20 antagonist, tumor necrosis factor-α antagonist）, p38 mitogen-activated protein kinase inhibitor, cholinergic receptor agonists, CD40/CD154 blockade, desmoglein 3 synthetic peptide, etc,have been gradually introduced into the treatment of pemphigus. However, high expense and lack of reliable clinical data have limited the wide use of these new modalities in pemphigus.

关 键 词：天疱疮 治疗 研究 

分 类 号：R758.66[医药卫生—皮肤病学与性病学]